News
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), is back in the green in 2025 as of the Apr. 21 close. Shares were down
UnitedHealth Group: Pariah to Pole Position to Buy the Dip Levels
UnitedHealth Group Inc. (NYSE: UNH) is a bellwether for the health insurance industry. The company symbolized the flaws in managed care organizations
Unitedhealth Stock: Dramatic 20% Plunge Shocks Market
UnitedHealth Group shares experienced a catastrophic drop on Thursday, plummeting by over 20% following disappointing first-quarter results. The healthcare giant saw its stock trading as low as
5 Winning Plays Outperforming the S&P This Year
While macroeconomic headwinds, tariffs, inflation, interest rates, and fears of a recession impact the broad market S&P 500, not all stocks are in the same position.
This is a look at five stocks
Verkauf bei Stärke in der Pharmaindustrie, rät Mizuho's Jared Holz
Die Auswirkungen von Zöllen auf Pharma-Aktien: Eine eingehende Analyse
Who Led Buybacks to End 2024? Hint: It Wasn’t Big Tech
Big tech has become known for its big-time use of buybacks. In the last quarter of 2024, Apple (NASDAQ: AAPL), Alphabet (NASDAQ: GOOG), Meta Platforms (NASDAQ: META), and Microsoft (NASDAQ: MSFT)
Johnson & Johnson Stock: Acquisition Progress Amid Talc Setback
Johnson & Johnson is advancing toward completing its strategic acquisition of Intra-Cellular Therapies, expected to finalize around April 2, 2025, following shareholder approval on March 27. The
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in
Johnson & Johnson Stock: Court Setback Triggers Financial Shift
Johnson & Johnson (J&J) faces a significant legal defeat as a US bankruptcy court in Texas rejected its subsidiary Red River Talc LLC's proposed settlement plan. This plan, valued at approximately
Rückschlag für Impfstoffaktien nach Rücktritt bei der FDA
Pfizer Stock: Probe Into COVID Vaccine Timing Claims
Pfizer shares are facing significant pressure following reports that Manhattan federal prosecutors are investigating serious allegations. The inquiry centers on claims made by British pharmaceutical
Merck Stock: Strategic $2B Chinese Partnership Boosts Portfolio
Merck & Co. has entered a landmark licensing agreement with Chinese pharmaceutical company Jiangsu Hengrui Pharmaceuticals for HRS-5346, an oral inhibitor targeting lipoprotein(a) formation for
Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow
In a market obsessed with the next big growth story, it’s easy to overlook the quiet power of consistency. As tariff turbulence continues, some investors are diverting a portion of their portfolio
Johnson & Johnson Stock: $55 Billion U.S. Investment Signals Growth
Johnson & Johnson (J&J) has announced plans to invest more than $55 billion in the United States over the next four years, representing a 25% increase compared to its spending during the previous
Johnson & Johnson Stock: Cancer Breakthroughs Amidst Market Challenges
Johnson & Johnson's stock recently experienced a slight setback, declining 1.14 percent to $162.38 amid challenging market conditions. However, the pharmaceutical giant's long-term outlook appears
Pfizer Stock: Company Sells Entire Haleon Stake
Pharmaceutical giant Pfizer has divested its complete shareholding in consumer health company Haleon for approximately £2.5 billion ($3.24 billion). The transaction was executed at 385 pence per
Starke Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus
Allschwil, 14. März 2025
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an
Johnson & Johnson Stock: Resilient Performance Amid Market Volatility
Healthcare giant Johnson & Johnson is demonstrating remarkable resilience in a volatile market environment. Currently trading at $165.68, the stock has established itself as a defensive asset
Merck Stock: Billion-Dollar Vaccine Facility Boosts US Presence
Merck, known internationally as MSD, has significantly strengthened its position in the American market with the opening of a new vaccine production facility in Durham, North Carolina. The
Pfizer Stock: Shares Drop Despite Cancer Drug Progress
Pfizer's stock fell 1.7% to $26.20 in Tuesday afternoon trading on the New York Stock Exchange, despite the company announcing promising results from a key clinical trial. The decline came amid
Johnson & Johnson Stock: New Cancer and Colitis Treatments Show Promise
Johnson & Johnson's stock could receive significant momentum following positive developments in multiple therapeutic areas. The company recently secured approval from Health Canada for a combination
BioNTech veröffentlicht Ergebnisse für das vierte Quartal und das Geschäftsjahr 2024 sowie Informationen zur Geschäftsentwicklung
- Onkologie-Pipeline weiterentwickelt mit mehr als 20 aktiven klinischen Phase-2- und Phase-3-Studien mit strategischem Fokus auf zwei tumorübergreifende (Pan-Tumor-)Programme:
Pfizer Stock: Nearing 52-Week Lows Amid Challenges
Pfizer's stock currently faces a challenging market position, trading precariously close to its 52-week lows. The shares recently showed minimal recovery, rising just 0.2 percent to $25.99 in New
Pfizer Stock: Court Ruling Clouds Positive Momentum
Pfizer shares gained 0.9 percent on Wednesday in New York trading, closing at $25.98 after reaching an intraday high of $26.17. Investor interest remained strong with over one million shares